Hepatitis Treatment News : Gilead’s Interferon-Free Sofosbuvir Regimen Is on Track for FDA Filing
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hep Newsletter
Join Us:

Back to home » Hepatitis Treatment News » February 2013


February 22, 2013

Gilead’s Interferon-Free Sofosbuvir Regimen Is on Track for FDA Filing

Gilead Sciences has announced promising Phase III results from a trial of the hepatitis C antiviral sofosbuvir, opening the door for regulatory filing this spring for a new interferon-free treatment for the disease. In the FUSION study, 195 participants who had failed a previous therapy and were infected with either genotype 2 or 3 of the hepatitis C virus (HCV) were randomly divided into two even groups to receive either 12 or 16 weeks of sofosbuvir (400 mg) plus ribavirin (1,000 or 1,200 mg) once a day.

On average, 50 percent of those in the 12-week arm and 73 percent of those in the 16-week arm achieved a sustained virologic response 12 weeks after completing treatment (SVR12, considered a cure). Eighty-six percent of those with genotype 2 in the 12-week arm achieved SVR12, and 30 percent of the genotype 3 participants achieved SVR12. Ninety-four percent of those with genotype 2 and 62 percent of those with genotype 3 achieved SVR12 in the 16-week arm.

Thirty-four percent of the participants had compensated cirrhosis at the beginning of the study; 31 percent of them achieved SVR12 in the 12-week arm; and 66 percent did so in the 16-week arm.

There were no discontinuations due to adverse effects. The most common side effects (reported in 15 percent or more of the participants) were fatigue, headache, insomnia and nausea.

These results, along with those from three other Phase III trials of sofosbuvir, will all support Gilead’s imminent regulatory filing.

To read the Gilead release, click here.

For a link to topline results from the study, click here.

Search: Gilead Sciences, sofosbuvir, FDA, U.S. Food and Drug Administration, regulatory filing, Phase II results, hepatitis C, HCV, virus, FUSION, genotype 2 or 3, ribavirin, interferon-free, SVR, sustained virologic response, compensated cirrhosis, fatigue, headache, insomnia, nausea.

Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Quick Links
Current Issue
Hep TV
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis C
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
Tell us what you think
Are you a regular coffee drinker?

Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.